

SUPPLEMENTARY DATA

Table S1.

Table S1. High Throughput Screening validation by statistical parameters

	$V_{PBP3} \pm SD$	$V_{S2d} \pm SD$	S/N	Z'factor	$CV_{PBP3} \pm SD$	$CV_{S2d} \pm SD$
HTS assay	8.81 ± 0.68 ($n = 378$)	1.29 ± 0.19 ($n = 378$)	41.77	0.70	0.60 ± 0.3	0.98 ± 0.34

V_{PBP3} : Mean of Positive Control (PC) was defined as the activity of P^A PBP3 in presence of D-alanine; V_{S2d} : Mean of Negative Control was defined as the S2d spontaneous hydrolysis; SD: Standard Deviations were calculated from the data obtained; S/N: Signal-to-Noise ratio indicates the difference between the PC and NC; an excellent assay should have a Z' factor between 0.5 and 1; CV: Coefficient of Variation of each signal is acceptable if < 20%.

Table S2

Table S2. Pyrrolidine 2,3-dione screening hits without concentration-dependent inhibition

Compound	Source	Biochemical inhibition of P^A PBP3	
		Inhibition at 100 μ M compound (%)	IC ₅₀ (μ M) S2d-TP Assay
10	ChemDiv F455-0278	60 ± 21	>100
11	ChemDiv F455-0164	86 ± 7	>100
12	ChemDiv F455-0912	76 ± 32	>100
13	ChemDiv F455-0267	85 ± 7	>100
14	ChemDiv F455-0279	70 ± 19	>100
15	ChemDiv F455-0467	71 ± 12	>100
16	ChemDiv F455-0396	65 ± 11	>100
17	ChemDiv F455-0454	95 ± 4	>100
18	ChemDiv	70 ± 21	>100
19	ChemDiv F455-0609	98 ± 4	>100
20	ChemDiv F455-0624	71 ± 13	>100
21	ChemDiv F455-0762	78 ± 31	>100
22	ChemDiv F455-0588	88 ± 14	>100
23	ChemDiv F455-0758	78 ± 9	>100
24	ChemDiv F455-0187	66 ± 7	>100
25	ChemDiv F455-0644	70 ± 18	>100
26	ChemDiv F455-1012	87 ± 32	>100
27	ChemDiv F455-1004	78 ± 30	>100
28	ChemDiv R095-0004	57 ± 57	>100
29	ChemDiv F455-1003	84 ± 27	>100
30	ChemDiv F455-1013	87 ± 22	>100

Table S3

Table S3. Minimal Inhibitory Concentrations of pyrrolidine-2,3-dione against wild-type strains

	MIC (μM) against different strains							
	<i>P. aeruginosa</i> ^a		<i>E. coli</i>	<i>K. pneumoniae</i>	<i>A. baumannii</i>	<i>S. pneumoniae</i>	<i>B. subtilis</i>	<i>S. aureus</i>
	PAO1	K2896	Neumann	clinical isolate	ATCC15308 ^b		168	133
1	>100	12.5	>100	>100	>100	25	>100	>100
32	>100	>100	>100	>100	>100	>100	100	>100
33	>100	>100	>100	>100	>100	50	>100	>100
34	3.13	12.5	>100	>100	>100	12.5	25	6.25
35	3.13	12.5	>100	>100	>100	6.25	6.25	3.13
36	>100	100	>100	>100	>100	>100	>100	>100
37	6.25	12.5	>100	>100	>100	50	3.13	6.25
38	>100	>100	>100	>100	>100	25	>100	>100
39	6.25	25	>100	>100	>100	25	>100	25
40	25	>100	>100	>100	>100	12.5	>100	>100
41	>100	25	>100	>100	>100	50	>100	>100
42	>100	>100	>100	>100	>100	>100	>100	>100
43	>100	>100	>100	6.25–3.13	>100	>100	>100	>100
44	>100	>100	>100	>100	>100	>100	>100	>100
45	>100	>100	>100	>100	>100	25	>100	6.25

^a 4 μg/mL PMBN, ^b 10 μg/mL PMBN

TABLE S4

Table S4. MIC of control compounds against selected strains.

Strain Name	PMBN (μg/ mL)	MIC (μM) against selected bacteria ¹	
		Aztreonam	Tygecyclin
<i>P. aeruginosa</i> PAO1	4	0.58	0.4
	0	>1.2	>4
<i>P. aeruginosa</i> K2896	4	0.29	0.2
	0	0.575	0.8
<i>E. coli</i> Neumann	0	0.287	0.4
<i>A. baumannii</i> ATCC15308	50	0.58	0.4
	0	>1.2	0.9
<i>K. pneumoniae</i> clinical isolate	50	0.071	0.4
	0	0.143	0.9
<i>S. pneumoniae</i>	0	>1.2	0.1
<i>B. subtilis</i> 168	0	>1.2	0.2
<i>S. aureus</i> 133	0	>1.2	0.2

¹ Values represent the median of at least three independent experiments

Table S5

Table S5. Detailed cytotoxicity of pyrrolidine-2,3-dione against four eukaryotic cell lines

Compound	Cytotoxicity effect (μM)			
	Epithelial liver HepG2	Epithelial kidney NRK52E	T-lymphoblast CCRF-CEM	T-lymphocyte H9
1	>100	>100	>100	>100
32	>100	98 ± 5	94 ± 6	>100
33	>100	84 ± 5	58 ± 6	>100
34	>100	>100	>100	>100
35	>100	53 ± 5	>100	96 ± 7
36	1 ± 2	58 ± 3	9 ± 4	48 ± 2
37	20 ± 4	9 ± 12	8 ± 6	19 ± 6
38	>100	>100	>100	>100
39	>100	>100	>100	>100
40	>100	>100	93 ± 4	>100
41	>100	>100	>100	>100
42	>100	>100	>100	>100
43	>100	73 ± 9.2	>100	>100
44	>100	52 ± 3	>100	>100
45	23 ± 8	23 ± 11	52 ± 8	32 ± 10
Cycloheximide	1.34 ± 0.7	0.20 ± 0.2	0.66 ± 0.5	0.53 ± 0.3

Table S6



Table S6. Eukaryotic cell and culture media

Cell line	Media composition
CCRF-CEM ATCC® CCL-119™	RPMI 1640 PAN
	L-Glutamine 2,0 g/L NaHCO ₃ , 10% FCS, 1% L-Glutamine, 1% Pen/Strep
Huh 7 (Prof. Bartenschlager, Heidelberg University)	DMEM PAN
	+ 4,5 g/L Glucose, L-Glutamine, Pyruvate, 3,7 g/L NaHCO ₃ , 10% FCS, 1% L-Glutamine, 1% Pen/Strep, 1% NEAA
HepG2 ATCC® HB-8065™	MEM PAN
	+ 4,5 g/L Glucose, L-Glutamine, Pyruvate, 3,7 g/L NaHCO ₃ , 10% FCS, 1% L-Glutamine, 1% Pen/Strep, 1% NEAA
NRK52E ATCC® CRL-1571™	DMEM PAN
	+ 4,5 g/L Glucose, L-Glutamine, Pyruvate, 3,7 g/L NaHCO ₃ , 10 % FCS, 1% Na-Pyruvate, 1% L-Glutamine, 1 % Pen/Strep


Figure S1: NMR Spectra of representative pyrroldine-2,3-diones:

Compound 1.



pdm3262.fid





File name: pdm3262.fid	Operator:	SF: 499.8279 MHz	NSC: 0	PW: 9.80 usec, RG: 12
Date: 16-May-2019	Solvent: dms0	SW: 8993 Hz	TE: 323 K	AQ: 1.78 sec, RD: 0.00 sec





Compound 32.



Compound 33.





Compound 34





Compound 35.

tr3963.fid




Compound 36.


¹H NMR spectrum of KK05-06:





Compound 37.





Compound 38.



Compound 39.




Compound 40.






Compound 41.


R1556042_T



R1556042_T C22H15BrClNO4 472.72






R1556042_C13_TC22H15BrClNO4472.72





Compound 42.



pdm5190.fid



Compound 43.



Compound 44.



Compound 45.

